

PATENT Attorney Docket No.: 07873.0002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Solco WALLE SCHALM et al.)	
Serial No.: 09/689,637)	Group Art Unit: 1614
Filed: October 13, 2000)	Examiner: Unassigned
For: COMBINED HEPATITIS B TF	REATME	ENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Preliminary Amendment

Before examining this application, please amend the claims as follows:

In the claims:

Please cancel claims 1-10 and re-write them as new claims 11-20 as follows:.

- --11. A method of treating a human patient infected with hepatitis B virus, which comprises administering to the patient both a nucleoside analogue and interferon-α during a period of at least 26 weeks.
- 12. A method according to claim 11, wherein the nucleoside analogue and interferon-α are administered at intervals ranging from daily to weekly.
- 13. A method according to claim 11, wherein the nucleoside analogue and interferon- α are both administered during a period of at least 30 weeks.
- 14. A method according to claim 11, wherein the period is preceded by a period wherein one of a nucleoside analogue and interferon-α is administered.
- 15. A method according to claim 11, wherein the period is followed by a period wherein one of a nucleoside analogue and interferon-α is administered.
- 16. A method according to claim 11, wherein the nucleoside analogue is lamivudine, adefovir or entecavir.